United States 
Canada
EU
UKWe’re proud to be part of such a tight-knit community. The more we can stay in touch, the closer we can work together. Click subscribe to receive news and updates about Amylyx.
Development and Preclinical Assessment of Antisense Oligonucleotides Targeting Calpain-2, a Critical Effector of Axonal Degeneration
Lead Author: Evan Mizerak (Presenter)
Published: TIDES
Date: May 7 - 10, 2023
Effect of an Oral, Fixed-Dose Combination of Sodium Phenylbutyrate and Taurursodiol on Long-Term Tracheostomy/Ventilation-Free Survival and Hospitalization in Amyotrophic Lateral Sclerosis: Final Results From CENTAUR
Lead Author: Janelle Schafer (Presenter)
Published: International Society for Pharmacoeconomics and Outcomes Research (ISPOR)
Date: May 6 - 10, 2023
Development and Preclinical Assessment of AMX0114: an Antisense Oligonucleotide Targeting Calpain-2, a Critical Effector of Axonal Degeneration
Lead Author: Joshua Cohen, Co-CEO and Co-Founder, Amylyx Pharmaceuticals
Published: Muscular Dystrophy Association (MDA)
Date: March 19 - 22, 2023
Expanded Access to Sodium Phenylbutyrate and Taurursodiol Coformulation in Amyotrophic Lateral Sclerosis: Updates and Initial Learnings
Lead Author: Sandy Morris, BA, BS, MBA & Philip Green, BS (Presenter)
Published: International Symposium on ALS-MND (MNDA)
Date: December 5 - 9, 2022
Independent Expert Review of Cardiac Adverse Events and Electrocardiographic Abnormalities and Parameters in a Phase 2 Trial of Sodium Phenylbutyrate and Taurursodiol in Amyotrophic Lateral Sclerosis (CENTAUR)
Lead Author: Shide Badri, MD, MPH
Published: International Symposium on ALS-MND (MNDA)
Date: December 5 - 9, 2022
Update on an International Phase 3 Trial Evaluating Sodium Phenylbutyrate and Taurursodiol in Amyotrophic Lateral Sclerosis (PHOENIX)
Lead Author: Leonard H. van den Berg, MD, PhD
Published: International Symposium on ALS-MND (MNDA)
Date: December 5 - 9, 2022
Cerebrospinal Fluid Biomarker Effects and Target Engagement From a Fixed-Dose Combination of Sodium Phenylbutyrate and Taurursodiol in Alzheimer’s Disease: Results From the PEGASUS Trial
Lead Author: Steven E. Arnold, MD
Published: Clinical Trials on Alzheimer’s Disease (CTAD)
Date: December 3, 2022
Development of AMX0114, an Antisense Oligonucleotide Targeting Calpain-2
Lead Author: Mathias Leinders, PhD
Published: Society for Neuroscience (SfN)
Date: November 12 - 16, 2022
Real-World Strategies to Enhance the Palatability of Coformulated Sodium Phenylbutyrate and Taurursodiol for the Treatment of Amyotrophic Lateral Sclerosis
Lead Author: Nicole Shuckett, RD
Published: Northeast ALS Consortium Annual Meeting (NEALS)
Date: November 2, 2022
Development and Preclinical Assessment of AMX0114: an Antisense Oligonucleotide Targeting Calpain-2, a Critical Effector of Axonal Degeneration
Lead Author: Joshua Cohen, Co-CEO and Co-Founder, Amylyx Pharmaceuticals
Published: Northeast ALS Consortium Annual Meeting (NEALS)
Date: November 1, 2022